We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$174M 8.76%
17,296,672
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.6B
$165M 8.28%
3,577,589
+211,059
+6% +$10.2M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$32.1B
$146M 7.36%
1,832,761
+729,286
+66% +$46.6M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$108M 5.41%
3,933,927
+74,949
+2% +$2.23M
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$76.9M 3.87%
734,553
– –
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$64.2M 3.23%
2,157,011
+17,737
+0.8% +$508K
PBYI icon
7
Puma Biotechnology
PBYI
$481M
$64.1M 3.23%
+733,320
New +$41M
TVTX icon
8
Travere Therapeutics
TVTX
$6.32B
$51.8M 2.61%
2,672,309
-135,216
-5% -$2.45M
TSRO
9
DELISTED
TESARO, Inc.
TSRO
$50.3M 2.53%
359,551
+118,523
+49% +$17.2M
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$50M 2.52%
3,448,302
+1,245,000
+57% +$15.6M
CORI
11
DELISTED
Corium International, Inc.
CORI
$43.6M 2.2%
5,847,133
+3,192,648
+120% +$19M
NXTM
12
DELISTED
NxStage Medical Inc.
NXTM
$39M 1.96%
1,555,523
-262,666
-14% -$6.5M
DOVA
13
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$38M 1.91%
+1,706,499
New +$35.9M
SRPT icon
14
Sarepta Therapeutics
SRPT
$2B
$36.7M 1.85%
1,089,961
-681,068
-38% -$22.2M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$140B
$35.7M 1.8%
277,352
-16,157
-6% -$1.94M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$3.82B
$32.1M 1.61%
4,363,114
+795,561
+22% +$5.06M
RDUS
17
DELISTED
Radius Health, Inc.
RDUS
$29.2M 1.47%
645,873
-264,999
-29% -$10.1M
VBIV
18
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$28.6M 1.44%
218,861
– –
XNCR icon
19
Xencor
XNCR
$2.18B
$27.3M 1.37%
1,293,095
-313,923
-20% -$7.04M
EVH icon
20
Evolent Health
EVH
$553M
$27.2M 1.37%
1,074,327
-370,173
-26% -$8.9M
RGNX icon
21
Regenxbio
RGNX
$588M
$27.1M 1.36%
1,371,186
-25,058
-2% -$485K
QTNT
22
DELISTED
Quotient Limited Ordinary Shares
QTNT
$26M 1.31%
92,862
+19,917
+27% +$5.62M
ANAB icon
23
AnaptysBio
ANAB
$1.73B
$22.8M 1.15%
952,269
+70,312
+8% +$1.77M
BPMC
24
DELISTED
Blueprint Medicines
BPMC
$22.5M 1.13%
444,661
-16,981
-4% -$721K
AVXS
25
DELISTED
AveXis, Inc. Common Stock
AVXS
$22.3M 1.12%
271,181
-177,320
-40% -$13.3M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.